Aspac Iii Acquisition CORP 10-Q quarterly reports

ASPAC III Acquisition Corp. reports continued operational inactivity and significant challenges, including a potential Nasdaq delisting and substantial doubt regarding its going concern status, as it seeks a business combination.

A SPAC III Acquisition Corp. reports a net loss of $113,988 for the first quarter of 2026 as it continues to pursue a business combination with Bioserica.

ASPAC III Acquisition Corp. reported a net income increase but faces substantial doubt about its going concern status following significant share redemptions and a reduced trust account balance.

A SPAC III Acquisition Corp. has entered into a definitive merger agreement with Bioserica International Limited, a bio-based antimicrobial materials company, valued at $217.86 million.

A SPAC III Acquisition Corp. reports a net income of $413,202 for the quarter ended March 31, 2025, driven by interest income from its trust account.

A SPAC III Acquisition Corp. reported a net loss for the three and nine months ended September 30, 2024, as it continues to seek a business combination target.